Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial

The Lancet

Volumn 373, Issue 9679, 2009, Pages 1949-1957

  Muñoz, Nubia ^a   Manalastas Jr , Ricardo ^b   Pitisuttithum, Punee ^c   Tresukosol, Damrong ^d   Monsonego, Joseph ^e   Ault, Kevin ^f   Clavel, Christine ^g   Luna, Joaquin ^a   Myers, Evan ^h   Hood, Sara ⁱ   Bautista, Oliver ⁱ   Bryan, Janine ⁱ   Taddeo, Frank J ⁱ   Esser, Mark T ⁱ   Vuocolo, Scott ⁱ   Haupt, Richard M ⁱ   Barr, Eliav ⁱ   Saah, Alfred ⁱ  

^a Instituto Nacional de Cancerología   (Colombia)

^b PHILIPPINE GENERAL HOSPITAL   (Philippines)

^c MAHIDOL UNIVERSITY   (Thailand)

^d KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^e Federation Mutualiste Parisienne   (France)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g REIMS UNIVERSITY HOSPITAL   (France)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TENSION HEADACHE; VERTIGO; VIRUS INFECTION;

EID: 66149161654     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60691-7     Document Type: Article

References (18)

1. Woodman C.B.J., Collins S., Winter H., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357 (2001) 1831-1836
2. Collins S., Mazloomzadeh S., Winter H., et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. Br J Obstet Gynaecol 109 (2002) 96-98
3. Winer R.L., Lee S.-K., Hughes J.P., Adam D.E., Kiviat N.B., and Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 (2003) 218-226
4. Munoz N., Mendez F., Posso H., et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 15 (2004) 2077-2087
5. de Sanjose S., Diaz M., Castellsagué X., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7 (2007) 453-459
6. Wellings K., Collumbien M., Slaymaker E., et al. Sexual behaviour in context: a global perspective. Lancet 368 (2006) 1706-1728
7. Betsey S., and Justin W. Marriage and divorce: changes and their driving forces. J Econ Pers 21 (2006) 27-52
8. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
9. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
10. The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virologic evidence of HPV infection. J Infect Dis 196 (2007) 1438-1446
11. Olsson S.-E., Villa L.L., Costa R., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like-particle vaccine. Vaccine 25 (2007) 4931-4939
12. Insinga R.P., Dasbach E.J., Elbasha E.H., Liaw K.L., and Barr E. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer 2 (2007) 15
13. Muñoz N., Castellsague X., de Gonzalez A.B., and Gissmann L. HPV in the etiology of human cancer. Vaccine 24 (2006) S1-S10
14. Solomon D., Davey D., Kurman R., et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287 (2002) 2114-2119
15. Opalka D., Lachman C.E., MacMullen S.A., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10 (2003) 108-115
16. WHO. Human papillomavirus infection and cervical cancer (2004), World Health Organization, Geneva. http://www.who.int/vaccine_research/diseases/hpv/en/ (accessed July 5, 2007).
17. Pagliusi S.R., and Aguado T.A. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23 (2004) 569-578
18. Hildesheim A., Herrero R., Wacholder S., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 (2007) 743-753